Explore a selection of our essential drug information below, or:
Identification
- Summary
Talc is a mineral used to prevent recurrence of malignant pleural effusions in symptomatic patients during thoracoscopy or open thoracotomy.
- Brand Names
- Sclerosol, Steritalc
- Generic Name
- Talc
- DrugBank Accession Number
- DB09511
- Background
Talc is a mineral composed primarily of magnesium, silicon and oxygen. It is a substance often found in cosmetic and personal hygiene products including baby powder, adult body powders and facial powders. Talc helps absorb moisture, freshen materials, and reduce friction to prevent rashes.
Although talc has been widely used for decades, lawsuits that have come to the surface claim serious health complications linked to its use. In fact, recent studies have reported that talc increases the risk of ovarian and endometrial cancers by approximately 30 percent.
- Type
- Small Molecule
- Groups
- Approved
- Structure
Structure for Talc (DB09511)
- Weight
- Average: 379.259
Monoisotopic: 377.81745674 - Chemical Formula
- H2Mg3O12Si4
- Synonyms
- E-553(III)
- Pulvis Talci
- Sterile talc powder
- Talc
- Talc Powder, Sterile
- Talco
- Talcum
Pharmacology
- Indication
Indicated to prevent recurrence of malignant pleural effusions in symptomatic patients during thoracoscopy or open thoracotomy.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to treat Diaper rash Combination Product in combination with: Zinc oxide (DB09321) ••• ••• •••••• Prophylaxis of Malignant pleural effusion •••••••••••• Management of Malignant pleural effusion •••••••••••• Used in combination to treat Skin irritation Combination Product in combination with: Zinc oxide (DB09321) ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
It has very good absorptive properties.
- Absorption
Intended for local use only.
- Volume of distribution
Intended for local use only.
- Protein binding
Intended for local use only.
- Metabolism
Intended for local use only.
- Route of elimination
Intended for local use only.
- Half-life
Intended for local use only.
- Clearance
Intended for local use only.
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
LC50: Not available.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlfacalcidol The serum concentration of Talc can be increased when it is combined with Alfacalcidol. Calcifediol The serum concentration of Talc can be increased when it is combined with Calcifediol. Calcitriol The serum concentration of Talc can be increased when it is combined with Calcitriol. Cholecalciferol The serum concentration of Talc can be increased when it is combined with Cholecalciferol. Cinoxacin Talc can cause a decrease in the absorption of Cinoxacin resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Sclerosol Aerosol, powder 4 g/25.0g Intrapleural Bryan Corporation 2013-06-30 Not applicable US 
Sterile Talc Powder 5 g/100mL Intrapleural Bryan Corporation 2003-12-15 Not applicable US Steritalc 2g Powder 2 g/50mL Intrapleural Novatech SA 2017-11-01 Not applicable US Steritalc 3g Powder 3 g/10mL Intrapleural Novatech SA 2017-11-01 Not applicable US Steritalc 4g Powder 4 g/50mL Intrapleural Novatech SA 2017-08-01 Not applicable US - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Baby Powder 100 g/100g Topical Walgreen Company 2014-07-17 Not applicable US Budpak Baby Powder 0.9 g/1g Topical Budpak Inc. 2014-07-07 2015-12-18 US Dusting Powder Powder 99 g/100g Topical Viny Health and Beauty Products Inc 2012-02-01 2017-10-26 US Health Smart Baby Powder 1 g/1g Topical Home Smart Products 2012-12-19 Not applicable US Natures Choice Baby Powder 99 g/100g Topical Unipack 2016-06-07 Not applicable US - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AHC Premium Intense Contour Balm Talc (2.05 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Aluminum hydroxide (0.45 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL) Cream Topical Carver Korea Co.,Ltd. 2014-01-15 2017-11-22 US Caldesene Talc (57.51 g/71g) + Zinc oxide (10.65 g/71g) Powder Topical Insight Pharmaceuticals 2009-07-09 2017-08-31 US Careline Perfect Care BB Talc (2.5 g/100g) + Allantoin (0.2 g/100g) + Caffeine (0.2 g/100g) + Octinoxate (4 g/100g) + Titanium dioxide (2.5 g/100g) Cream Topical Cosmopharm Ltd. 2015-09-17 2019-09-01 US Careline Perfect Care BB Talc (2.5 g/100g) + Allantoin (0.2 g/100g) + Caffeine (0.2 g/100g) + Octinoxate (4 g/100g) + Titanium dioxide (5 g/100g) Cream Topical Cosmopharm Ltd. 2015-09-17 2019-09-01 US Face It Hd Perfect Bb Spf30 Pa 01 Talc (0.684 mL/100mL) + Betaine (2 mL/100mL) + Octinoxate (6 mL/100mL) + Titanium dioxide (6.36 mL/100mL) + Zinc oxide (2.88 mL/100mL) Cream Topical Thefaceshop Co., Ltd. 2011-08-23 Not applicable US - Unapproved/Other Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image AHC Premium Intense Contour Balm Talc (2.05 g/50mL) + Adenosine (0.02 g/50mL) + Aluminium tristearate (0.04 g/50mL) + Aluminum hydroxide (0.45 g/50mL) + Arbutin (1 g/50mL) + Methicone (20 CST) (1.3 g/50mL) + Octinoxate (1.5 g/50mL) + Titanium dioxide (3.96 g/50mL) + Zinc oxide (0.96 g/50mL) Cream Topical Carver Korea Co.,Ltd. 2014-01-15 2017-11-22 US
Categories
- Drug Categories
- Classification
- Not classified
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 7SEV7J4R1U
- CAS number
- 14807-96-6
- InChI Key
- JACYTZHPXAPJCY-UHFFFAOYSA-L
- InChI
- InChI=1S/3Mg.2H2O.10O.4Si/h;;;2*1H2;;;;;;;;;;;;;;/q3*+2;;;10*-2;4*+4/p-2
- IUPAC Name
- tetrasilicon(4+) trimagnesium(2+) dihydroxide decaoxidandiide
- SMILES
- [O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[O--].[Mg++].[Mg++].[Mg++].[Si+4].[Si+4].[Si+4].[Si+4].[O-][H].[O-][H]
References
- General References
- External Links
Clinical Trials
- Clinical Trials
Clinical Trial & Rare Diseases Add-on Data Package
Explore 4,000+ rare diseases, orphan drugs & condition pairs, clinical trial why stopped data, & more. Preview package Phase Status Purpose Conditions Count Start Date Why Stopped 100+ additional columns Unlock 175K+ rows when you subscribe.View sample dataNot Available Completed Not Available Pleuritis 1 somestatus stop reason just information to hide Not Available Unknown Status Treatment Malignant Pleural Effusion / Pleural Diseases / Pleural Effusions 1 somestatus stop reason just information to hide 4 Completed Treatment Pleural Effusions 1 somestatus stop reason just information to hide 4 Terminated Treatment Malignant Pleural Effusion 1 somestatus stop reason just information to hide 3 Completed Prevention Syndrome, Metabolic 1 somestatus stop reason just information to hide
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Powder Topical 100 g/100g Powder Topical 0.9 g/1g Cream Topical Aerosol Topical Powder Topical 1 g/1g Powder Topical 99 g/100g Powder Topical Aerosol, powder Intrapleural 4 g/25.0g Powder Intrapleural 5 g/100mL Powder Intrapleural 2 g/50mL Powder Intrapleural 3 g/10mL Powder Intrapleural 4 g/50mL - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP -0.65 Chemaxon pKa (Strongest Acidic) 15.7 Chemaxon pKa (Strongest Basic) -1.8 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 1 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 0 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 13.91 m3·mol-1 Chemaxon Polarizability 1.19 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 30, 2015 19:10 / Updated at July 18, 2023 22:56